Role of tyrosine kinase inhibitors in tumor immunology

Immunotherapy

Volumn 3, Issue 1, 2011, Pages 107-116

  Nishioka, Yasuhiko ^a   Aono, Yoshinori ^a   Sone, Saburo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

dendritic cell; myeloid derived suppressor cell; regulatory T cell; tyrosine kinase inhibitor

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; DASATINIB; DENDRITIC CELL VACCINE; IMATINIB; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB;

ANGIOGENESIS; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFECT; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTINEOPLASTIC AGENTS; DENDRITIC CELLS; HUMANS; INDOLES; MICE; MYELOID CELLS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRROLES; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 78650569157     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.79     Document Type: Review

References (111)

1. Zhang J, Yang PL, Gray NS: Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39 (2009).
2. Agrawal M, Garg RJ, Cortes J, Quintás-Cardama A: Tyrosine kinase inhibitors: the first decade. Curr. Hematol. Malig. Rep. 5, 70-80 (2010).
3. Sharma SV, Haber DA, Settleman J: Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat. Rev. Cancer 10, 241-253 (2010).
4. Knight ZA, Lin H, Shokat KM: Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10, 130-137 (2010). n Summary of US FDA-approved TKIs and their targets.
5. Druker BJ, Talpaz M, Resta DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001). (Pubitemid 32267972)
6. Demetri GD, von Mehren M, Blanke CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002). (Pubitemid 34879334)
7. van Oosterom AT, Judson I, Verweij J et al.: European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet 358, 1421-1423 (2001).
8. Druker BJ, Tamura S, Buchdunger E et al.: Effects of s selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat. Med. 2, 561-566 (1996). (Pubitemid 26151518)
9. Steeghs N, Nortier JW, Gelderblom H: Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann. Surg. Oncol. 14, 942-953 (2007). (Pubitemid 46175346)
10. Le Tourneau C, Faivre S, Raymond E: New developments in multitargeted therapy for patients with solid tumours. Cancer Treat. Rev. 34, 37-48 (2008). (Pubitemid 351168610)
11. Grant SK: Therapeutic protein kinase inhibitors. Cell Mol. Life Sci. 66, 1163-1177 (2009).
12. Fukuoka M, Yano S, Giaccone G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J. Clin. Oncol. 21, 2237-2246 (2003). (Pubitemid 46621858)
13. Kris MG, Natale RB, Herbst RS et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149-2158 (2003). (Pubitemid 37432975)
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al.: Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005).
15. Escudier B, Eisen T, Stadler WM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007). (Pubitemid 46089673)
16. Llovet JM, Ricci S, Mazzaferro V et al.: Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
17. Motzer RJ, Hutson TE, Tomczak P et al.: Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007). (Pubitemid 46089672)
18. Motzer RJ, Hutson TE, Tomczak P et al.: Overall survival and updated results for sunitinib compared with interferon a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009).
19. Gorre ME, Mohammed M, Ellwood K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001). (Pubitemid 32743979)
20. Tamborini E, Bonadiman L, Greco A et al.: A new mutation in the Kit ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127, 294-299 (2004). (Pubitemid 38962296)
21. Pao W, Miller VA, Politi KA et al.: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, E73 (2005). (Pubitemid 40629469)
22. Engelman JA, Zejnullahu K, Mitsudomi T et al.: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007). n Demonstrates the resistance mechanism of TKI. (Pubitemid 46799492)
23. Sergina NV, Rausch M, Wang D et al.: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437-441 (2007). (Pubitemid 46160912)
24. Yano S, Wang W, Li Q et al.: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68, 9479-9487 (2008).
25. + myeloid cells. (Pubitemid 47236916)
26. Shojaei F, Wu X, Qu X et al.: G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl Acad. Sci. USA 106, 6742-6747 (2009). n Describes the relationship of anti-VEGF therapy and myeloid cells.
27. Ko JS, Rayman P, Ireland J et al.: Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 70, 3526-3536 (2010). nn Novel finding regarding the role of granulocyte-macrophage-colony stimulating factor in the effects of sunitinib on myeloid-derived suppressor cells (MDSCs).
28. Blattman JN, Greenberg PD: Cancer immunotherapy: a treatment for the masses. Science 305, 200-205 (2004).
29. Melief CJ: Cancer immunotherapy by dendritic cells. Immunity 29, 372-383 (2008). n Representative review of cancer immunotherapy with dendritic cells (DCs).
30. Steinman RM, Banchereau J: Taking dendritic cells into medicine. Nature 449, 419-426 (2007). (Pubitemid 47509552)
31. Palucka AK, Ueno H, Fay JW, Banchereau J: Taming cancer by inducing immunity via dendritic cells. Immunol. Rev. 220, 129-150 (2007). (Pubitemid 350045575)
32. Kalinski P, Mailliard RB, Giermasz A et al.: Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert. Opin. Biol. Ther. 5, 1303-1315 (2005). (Pubitemid 41503042)
33. 3+ blood dendritic cells enhance NK cell-mediated cytotoxicity. Eur. J. Immunol. 31, 2633-2641 (2001). (Pubitemid 32898730)
34. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H: Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin-12. Cancer Res. 59, 4035-4041 (1999). (Pubitemid 29393574)
35. Jefford M, Maraskovsky E, Cebon J, Davis ID: The use of dendritic cells in cancer therapy. Lancet Oncol. 2, 343-353 (2001). (Pubitemid 33585939)
36. Steinman RM, Dhodapkar M: Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 94, 459-473 (2001). n Summary of DC-based immunotherapy. (Pubitemid 32979535)
37. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004). n Important summary of clinical trials in cancer immunotherapy. (Pubitemid 39273730)
38. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM: Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol. Immunother. 58, 1-14 (2009).
39. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164 (1995). n Early report concerning the discovery of regulatory T (Treg) cells.
40. + Tregs and immune control. J. Clin. Invest. 114, 1209-1217 (2004), (Pubitemid 40385288)
41. Schwartz R: Natural regulatory T cells and self-tolerance. Nat. Immunol. 6, 327-330 (2005). (Pubitemid 41716768)
42. Sakaguchi S, Yamaguchi T, Nomura T, Ono M: Regulatory T cells and immune tolerance. Cell 133, 775-787 (2008). n Representative review of Treg cells. (Pubitemid 351707693)
43. Wing K, Sakaguchi S: Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 11, 7-13 (2010).
44. Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I: The significance of Treg cells in defective tumor immunity. Arch. Immunol. Ther. Exp. (Warsz.) 56, 181-191 (2008).
45. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61, 4766-4772 (2001).
46. Woo EY, Yeh H, Chu CS et al.: Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168, 4272-4276 (2002). (Pubitemid 34441324)
47. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9, 606-612 (2003). (Pubitemid 36182591)
48. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 9, 4404-4408 (2003). (Pubitemid 37248397)
49. Liyanage UK, Moore TT, Joo HG et al.: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756-2761 (2002).
50. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65, 2457-2464 (2005). n Representative report of Treg cells in cancer patients. (Pubitemid 40490158)
51. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98, 1089-1099 (2003). (Pubitemid 37022112)
52. +CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J. Surg. Res. 124, 151-157 (2005). (Pubitemid 40269816)
53. +CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol. Immunother. 55, 1064-1071 (2005). (Pubitemid 43800721)
54. + human thymocytes. J. Exp. Med. 196, 379-387 (2002). nn Summary of immunosuppressive mechanisms by Treg cells. (Pubitemid 34879113)
55. + regulatory T cells is mediated by cell surface-bound transforming growth factorβ. J. Exp. Med. 194, 629-644 (2001). n One of the studies demonstrating the mechanism of immunosuppressive functions of Treg cells. (Pubitemid 32844773)
56. Kitani A, Fuss I, Nakamura K, Kumaki F, Usui T, Strober W: Transforming growth factor (TGF)-b1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-β1-mediated fibrosis. J. Exp. Med. 198, 1179-1188 (2003). n One of the studies demonstrating the mechanism of immunosuppressive functions of Treg cells. (Pubitemid 37323383)
57. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295-302 (2000). n One of the studies demonstrating the mechanism of immunosuppressive functions of Treg cells. (Pubitemid 30470312)
58. Hara M, Kingsley CI, Niimi M et al.: IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J. Immunol. 166, 3789-3796 (2001). (Pubitemid 32224903)
59. Ostroukhova M, Qi Z, Oriss TB, Dixon-McCarthy B, Ray P, Ray A: Treg-mediated immunosuppression involves activation of the Notch-HES1 axis by membrane-bound TGF-β. J. Clin. Invest. 116, 996-1004 (2006).
60. Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174 (2009). nn Critical review of MDSCs.
61. Ostrand-Rosenberg S, Sinha P: Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182, 4499-4506 (2009).
62. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V: Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222, 162-179 (2008). (Pubitemid 351430364)
63. Gabrilovich D: Mechanisms and functional significance of tumor-induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941-952 (2004). nn Critical review of tumor-induced immunosuppression for DC functions. (Pubitemid 39620069)
64. Almand B, Clark JI, Nikitina E et al.: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166, 678-689 (2001). n Early report of MDSCs. (Pubitemid 32038493)
65. Movahedi K, Guilliams M, Van den Bossche J et al.: Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111, 4233-4244 (2008).
66. + myeloid cells. J. Immunol. 166, 5398-5406 (2001). (Pubitemid 32374159)
67. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI: Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J. Immunol. 184, 3106-3116 (2010). n Describes the immunosuppresive mechanisms of MDSCs.
68. Murdoch C, Muthana M, Coffelt SB, Lewis CE: The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8, 618-631 (2008). nn Critical review of myeloid cell-mediated tumor angiogenesis.
69. Schmid MC, Varner JA: Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J. Oncol. DOI: 10.1155/2010/201026. (2010) (Epub ahead of print).
70. Shojaei F, Wu X, Zhong C et al.: Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450, 825-831 (2007). (Pubitemid 350231321)
71. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6, 409-421 (2004). n Direct evidence regarding the relationship between MDSCs and tumor angiogenesis. (Pubitemid 39361441)
72. Cools J, DeAngelo DJ, Gotlib J et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201-1214 (2003). (Pubitemid 36359296)
73. Appel S, Rupf A, Week MM et al.: Effects of imatinib on monocyte-derived dendritic cels are mediated by inhibition of nuclear factor-kB and Akt signaling pathway. Clin. Cancer Res. 11, 1928-1940 (2005). (Pubitemid 40471859)
74. Seggewiss R, Loré K, Greiner E et al.: Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105, 2473-2479 (2005). (Pubitemid 40387048)
75. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S: Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104, 1094-1099 (2004). n Report of the immunosuppresive effects of imatinib. (Pubitemid 39038030)
76. + peripheral blood progenitor cells. Blood 103, 538-544 (2004). (Pubitemid 38140084)
77. Taieb J, Maruyama K, Borg C et al.: Imatinib impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood 103, 1966-1967 (2004).
78. + and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. J. Leukoc. Biol. 79, 747-756 (2006) (Pubitemid 44835607)
79. Mohty M, jourdan F, Mami NB et al.: Imatinib and plasmocytoid dendritic cell function in patients with chronic myelogenous leukemia. Blood 103, 4666-4668 (2004). (Pubitemid 38746000)
80. Sato N, Narita M, Takahashi M et al.: The effects of STI571 on antigen-presentation of dendritic cells generated from patients with chironic myelogenous leukemia. Hematol. Oncol. 21, 67-75 (2003). (Pubitemid 36717431)
81. + T-cell tolerance. Blood 105, 1135-1143 (2005). (Pubitemid 40170886)
82. Borg C, Terme M, Taïeb J et al.: Novel mode of action of c-Kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114, 379-388 (2004). nn Early report regarding the effects of imatinib on NK cell activity. (Pubitemid 39071610)
83. Dewar AL, Cambareri AC, Zannettino AC et al.: Macrophage colony-stimulating factor receptor c-Fms is a novel target of imatinib. Blood 105, 3127-3132 (2005). (Pubitemid 40504330)
84. Taylor JR, Brownlow N, Domin J, Dibb NJ: FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene 25, 147-151 (2006). (Pubitemid 43050013)
85. Gabrilovich DI, Chen HL, Girgis KR et al.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096-1103 (1996). nn First report regarding VEGF-mediated suppression of DC function. (Pubitemid 26338628)
86. Ohm JE, Shurin MR, Esche C, Lotze MT, Carbone DP, Gabrilovich DI: Effect of vascular endothelial growth factor and Flt3 ligand on dendritic cell generation in vivo. J. Immunol. 163, 3260-3268 (1999). (Pubitemid 29431827)
87. Oyama T, Ran S, Ishida T et al.: Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kB activation in hemopoietic progenitor cells. J. Immunol. 160, 1224-1232 (1998). (Pubitemid 28093419)
88. Ishida T, Oyama T, Carbone DP, Gabrilovich DI: Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J. Immunol. 161, 4842-4851 (1998). (Pubitemid 28492062)
89. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP: Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5, 2963-2970 (1999). (Pubitemid 29493976)
90. + dendritic cell frequency predicts progression-free survival. Clin. Cancer Res. 14, 5884-5892 (2008).
91. Hipp MM, Hilf N, Walter S et al.: Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111, 5610-5620 (2008). nn Describes the immunomodulatory effects of sorafenib and sunitinib.
92. Zhao W, Gu YH, Song R, Qu BQ, Xu Q: Sorafenib inhibits activation of human peripheral blood T cells by targeting Lck phosphorylation. Leukemia 22, 1226-1233 (2008). (Pubitemid 351833791)
93. Ozao-Choy J, Ma G, Kao J et al.: The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69, 2514-2522 (2009). n Report on the immunostimulatory effects of sunitinib.
94. Pan PY, Wang GX, Yin B et al.: Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111, 219-228 (2008). n Novel mechanism to block MDSC development.
95. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H: Sunitinib inhibition of STAT3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69, 2506-2513 (2009).
96. Ko JS, Zea AH, Rini BI et al.: Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15, 2148-2157 (2009). nn Representative report describing the immunostimulatory effects of sunitinib in cancer patients.
97. Lombardo LJ, Lee FY, Chen P et al.: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl) -2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661 (2004). (Pubitemid 40053752)
98. Talpaz M, Shah NP, Kantarjian H et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531-2541 (2006). (Pubitemid 43882349)
99. Wu J, Meng F, Kong LY et al.: Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J. Natl Cancer Inst. 100, 926-939 (2008). (Pubitemid 351957515)
100. Weichsel R, Dix C, Wooldridge L et al.: Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin. Cancer Res. 14, 2488-2491 (2008). (Pubitemid 351551084)
101. + T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp. Hematol. 37, 256-265 (2009).
102. Fraser CK, Lousberg EL, Kumar R, Hughes TP, Diener KR, Hayball JD: Dasatinib inhibits the secretion of TNF-α following TLR stimulation in vitro and in vivo. Exp. Hematol. 37, 1435-1444 (2009).
103. + regulatory T cells. Br. J. Haematol. 144, 195-205 (2009).
104. Ghoreschi K, Laurence A, O'Shea JJ: Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat. Immunol. 10, 56-360 (2009).
105. Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A: Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev. 27, 31-40 (2008). nn Representative review of myeloid cell-mediated angiogenesis.
106. van Dongen M, Savage ND, Jordanova ES et al.: Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int. J. Cancer. 127, 899-909 (2010).
107. McLean K, Buckanovich RJ: Myeloid cells functioning in tumor vascularization as a novel therapeutic target. Transl. Res. 151, 59-67 (2008). nn Review of myeloid cell-mediated angiogenesis.
108. Fainaru O, Almog N, Yung CW et al.: Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. FASEB J. 24, 1411-1418 (2010). nn Direct demonstration of the contribution of immature DCs to angiogenesis.
109. Conejo-Garcia JR, Benencia F, Courreges MC et al.: Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of VEGF-A. Nat. Med. 10, 950-958 (2004). n First report describing the role of DCs in vasculogenesis. (Pubitemid 39273736)
110. Kishuku M, Nishioka Y, Abe S et al.: Expression of soluble vascular endothelial growth factor receptor-1 in human monocyte-derived mature dendritic cells contributes to their antiangiogenic property. J. Immunol. 183, 8176-8185 (2009).
111. Coukos G, Benencia F, Buckanovich RJ, Conejo-Garcia JR: The role of dendritic cell precursors in tumour vasculogenesis. Br. J. Cancer. 92, 1182-1187 (2005). n Concise review of the role of DCs in angiogenesis. (Pubitemid 40604389)